Question explored with the scientific record
Oxford–AstraZeneca COVID-19 vaccine side effacts?
The AstraZeneca shot hits hard and fast: most people feel it, and a small but real minority get serious blood-clotting or nervous-system injuries.
The common side effects are not subtle. In one Korean study of 1,431 healthcare workers, about 91 in 100 reported an adverse event after the first dose, with injection-site pain in about 78 in 100, muscle aches in 61, fatigue in 51, headache in 47, and fever in 36 [1]. A second Korean study found nearly everyone (about 99 in 100) reported some reaction, with fatigue in 95 and headache in 85 [2]. A Sri Lankan survey of 836 doctors found reactions started about 11 hours after the shot and lasted about a day and a half [5]. Most resolved quickly, but one Togo study found about 24 in 100 health workers reported severe events, concentrated in younger and female recipients [3].
The serious risks are where the burden of proof matters. The most documented is vaccine-induced immune thrombotic thrombocytopenia (VITT), a condition where the body makes antibodies against its own platelets, causing clots and low platelet counts. The mechanism is now well characterized: the vaccine's contents bind to platelet factor 4, triggering platelet activation and neutrophil NETosis [9][11][13]. Incidence estimates from national surveillance ranged from about 1 in 26,500 in Norway to 1 in 93,400 in the UK [10][14]. A meta-analysis found vector vaccines like this one raised the odds of the clot-plus-low-platelets form of cerebral venous sinus thrombosis by about 52-fold compared to other clot types, with a 13-fold higher in-hospital death rate [8]. A review of 552 worldwide cases found 37 in 100 died [15]. Other serious events documented in case reports include transverse myelitis (3 cases in 11,636 trial participants, which the authors called "extremely high" against a background of 0.5 per million) [4], autoimmune encephalitis [7], and persistent joint and muscle pain lasting weeks [6].
The evidence base has real limits. Most studies are short-term, self-reported surveys of healthcare workers, not long-term tracking of the general population. The manufacturer-funded trials reported serious events in 0.7% of vaccinated versus 0.8% of placebo [12], but that comparison cannot capture rare events like VITT, which emerged only after millions of doses were given. No retrieved study compared vaccinated people to a genuinely unvaccinated control group over years. The passive surveillance systems that caught VITT detect only a fraction of what happens.
| Adverse event | Rate or frequency |
|---|---|
| Any reaction after dose 1 | 91–99 in 100 [1][2] |
| Injection-site pain | 78 in 100 [1] |
| Fatigue | 51–95 in 100 [1][2] |
| Severe events (Togo) | 24 in 100 [3] |
| VITT (Norway) | 1 in 26,500 [10][14] |
| VITT (UK) | 1 in 93,400 [10][14] |
| CVST death rate | 37 in 100 [15] |
My call: this vaccine produces common, unpleasant reactions in nearly everyone and rare but potentially fatal blood-clotting and neurological injuries in a small minority. The risk is real, mechanistically explained, and was not detectable in the pre-approval trials. Confidence: high on the common side effects and the existence of VITT; moderate on the exact incidence rates, which vary by country and surveillance method.
Sources used 15
-
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
This study investigates the adverse events reported by healthcare workers after receiving the first dose of either the ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccines, revealing a significantly higher incidence of adverse events in the ChAdOx1 nCoV-19 group compared to the BN…
DOI: 10.3346/jkms.2021.36.e107 -
Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
This study investigates the adverse events following immunization (AEFIs) associated with the first and second doses of the ChAdOx1 nCoV-19 vaccine among healthcare workers in Korea, finding that AEFIs were generally tolerable and less severe after the second dose compared to th…
DOI: 10.3390/vaccines9101096 -
Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
This study investigates the prevalence of severe adverse events among health professionals in Togo following the first dose of the ChAdOx1 nCoV-19 vaccine, revealing a 23.8% incidence of such events, particularly among younger and female participants.
DOI: 10.1186/s13690-021-00741-x -
Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222)
A clinical review of 43 COVID-19-associated acute transverse myelitis (ATM) cases and 3 post-vaccination ATM adverse events with the ChAdOx1 nCoV-19 vaccine, finding an ATM incidence of 0.5 per million COVID-19 cases and proposing immune-mediated pathogenic mechanisms with short…
DOI: 10.3389/fimmu.2021.653786 -
Study on the adverse events following immunization (AEFI) of ChAdOx1 nCoV-19 vaccine in a group of Sri Lankan medical officers
An online retrospective survey of Sri Lankan medical officers found a high incidence of adverse events following immunization (AEFI) after the first dose of ChAdOx1 nCoV-19, with common symptoms including body ache, lethargy, local site reactions, fever, and chills, onset around…
DOI: 10.4038/sljid.v12i1.8423 -
Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
This study reports five cases of persistent polyarthralgia and myalgia syndrome in patients who received the ChAdOx1 nCOV-19 (AstraZeneca) vaccine, highlighting the need for further monitoring of potential adverse events following COVID-19 vaccination.
DOI: 10.3346/jkms.2021.36.e245 -
Autoimmune Encephalitis as an Adverse Event of COVID-19 Vaccination
This case report describes a rare instance of autoimmune encephalitis occurring in a 35-year-old female patient following her first dose of the ChAdOx1 nCoV-19 vaccine, highlighting the need to consider serious adverse events associated with COVID-19 vaccinations.
DOI: 10.3988/jcn.2022.18.1.114 -
Cerebral venous sinus thrombosis in the setting of COVID-19 vaccination: a systematic review and meta-analysis
This systematic review and meta-analysis investigates the incidence and outcomes of cerebral venous sinus thrombosis (CVST) associated with COVID-19 vaccination, revealing that vector-based vaccines significantly increase the risk of thrombotic-thrombocytopenia syndrome (TTS) co…
DOI: 10.1007/s00415-022-11101-2 -
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines
This study compares the ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vaccines, revealing significant differences in their composition and functional properties that may contribute to the varying incidence rates of vaccine-induced thrombosis with thrombocytopenia syndrome (VITT/TTS…
DOI: 10.3324/haematol.2021.280154 -
Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia
This study reviews the phenomenon of vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with SARS-CoV-2 vaccines, detailing its clinical characteristics, incidence rates, and treatment recommendations.
DOI: 10.3345/cep.2021.00717 -
FcγRIIa - dependent platelet activation identified in COVID-19 vaccine-induced immune thrombotic thrombocytopenia-, heparin-induced thrombocytopenia, streptokinase- and anisoylated plasminogen-streptokinase activator complex-induced platelet activation
A narrative review examining how FcγRIIa-dependent platelet activation underlies vaccine-induced immune thrombotic thrombocytopenia (VITT) and parallels heparin-induced thrombocytopenia, streptokinase, and APSAC-induced platelet disorders, using comparative analysis to better un…
DOI: 10.3389/fcvm.2023.1282637 -
Adverse events following vaccination against coronavirus disease 2019
A narrative review of four COVID-19 vaccines used in Korea (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S) concludes they have acceptable safety profiles, with mostly mild transient AEFIs and rare serious events, so benefits outweigh risks.
DOI: 10.7180/kmj.22.017 -
NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia
This study investigates the mechanisms of vaccine-induced immune thrombotic thrombocytopenia (VITT), demonstrating that anti-PF4 antibodies activate neutrophils to induce NETosis and thrombosis, while also revealing distinct processes for thrombosis and thrombocytopenia.
DOI: 10.1038/s41467-022-32946-1 -
COVID-19: SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia
This study investigates the occurrence of vaccine-induced immune thrombotic thrombocytopenia (VITT) following SARS-CoV-2 vaccination, highlighting its clinical features, associated risks, and potential mechanisms.
DOI: 10.1055/a-1369-3488 -
Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases
This study analyzes 552 worldwide cases of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination, highlighting its rarity, demographic characteristics, clinical outcomes, and potential underlying mechanisms.
DOI: 10.3390/vaccines10020232